life expectancy decreases in US in 2015

The CDC just released the life expectancy statistics for the US from 2015, finding a decrease of 0.1 years from the 2014 numbers (see http://www.cdc.gov/nchs/products/databriefs/db267.htm  ).

Details:
--in 2015, there were 2,712,630 deaths, an increase in 86,212
--in 2015, life expectancy was 78.8 years, with 0.1 year decrease from 2014
   --for males, the decrease was 0.2 years from 76.5 to 76.3 in 2015
   --for females, the decrease was 0.1 years from 81.3 to 81.2 in 2015
   --for both, the change was only in life expectancy from birth, with no change in the group who made it to 65 yo [life expectancy for males aged 65 was 18.0 years, females 20.6 years: no change from 2014 to 2015. But no indication in their data as to why.  ??from more opiate deaths??]
--the age-adjusted death rate increased 1.2% from 724.6 deaths/100,000 to 733.1 in 2015
   --this increase was highest for non-Hispanic white females (1.6%), then non-Hispanic white males (1%), then non-Hispanic black males (0.9%)
--no change in 10 leading causes of death, but death rate increased for 8 of them and decreased for 1. (the 10 leading causes of death account for 74.2% of all deaths)
   --increased for heart disease with age-adjusted death rate increase from 167 to 168.5, chronic lower respiratory disease (40.5 to 41.6), unintentional injuries (40.5 to 43.2), stroke (36.5 to 37.6), Alzheimer’s (25.4 to 29.4), diabetes (20.9 to 21.3), kidney disease (13.2 to 13.4), and suicide (13.0 to 13.2), but decreased for cancer (161.2 to 158.5)),
--infant mortality rate was no different, at 589.5/100K live births (was 582.1 in 2014, reflecting 240 more infant deaths, but the only significant change was an 11.3% increase in unintentional injuries
--10 leading causes of infant death were the same, though 2 changed rankings (maternal complications moved from #3 to #4 and SIDS from #4 to #3) in 2015

So, though life expectancy in the US has increased pretty dramatically since around 1970, and has had a largely linear increase in the past couple of decades, this new data is concerning (and more concerning if the trend continues). And there may be several impending changes in US policies in the next several years which could exacerbate this trend, potentially with more uninsured people without access to health care, a decrease in the social safety net which provides some basic needs to poor and disabled, changes in abortion laws (which in the past has led to maternal mortality associated with getting illegal back-alley abortions), perhaps increasing trends in interpersonal violence (which we are starting to see now), even perhaps too-early/more accelerated FDA approval of new meds and medical devices with potentially more adverse outcomes, increased pollution and health effects from possibly gutting the EPA and empowering fossil fuel producers/accelerating climate change, increased worker deaths from relaxed regulations, the adverse social and health effects of increasing income inequality, etc etc etc etc…… [not a pretty picture]

See http://gmodestmedblogs.blogspot.com/2016/02/increasing-disparities-in-life.html and http://gmodestmedblogs.blogspot.com/2016/04/life-expectancy-and-income.html  which review studies showing that increasing longevity in the US tracks with income inequality

Comments

Post a Comment

if you would like to receive the near-daily emails regularly, please email me at gmodest@uphams.org

Popular posts from this blog

cystatin c: better predictor of bad outcomes than creatinine

  another article found significant discordance between creatinine and cystatin C in assessing renal function,  finding that the latter correlated most strongly with both renal and non-renal adverse clinical outcomes (see   ckd cystatin c better than creat AJKD2023  in  dropbox or doi: 10.1053/ j.ajkd.2023.04.002)   Details: -- 158,601 adults who were in the Stockholm Creatinine Measurements (SCREAM) project and had testing of creatinine and cystatin C on the same day during a healthcare encounter, from 2010-2018     -- >400,000 outpatient tests were done for both creatinine and cystatin C levels -- mean age 62, 48% female -- mean eGFR by creatinine (   eGFR cr ) 80; mean eGFR by cystatin C ( eGFR cys  ) 73 -- mean stage of renal insufficiency: 39%  eGFR cr   90+; 38%  eGFR cr  60-89; 12%  eGFR cr  45-59; 7.1%  eGFR cr  30-44; 3.2%  eGFR cr  15-29, 0.7%  eGFR cr ...
Read more

diabetes DPP-4 inhibitors and the risk of heart failure

the FDA just came out with a safety alert about 2 DPP-4 inhibitors and the increased risk of heart failure (released 04/05/2016)(see  http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm494252.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery ​ ). details: --saxagliptin and alogliptin were singled out because of 2 clinical trials in diabetic patients with heart disease. in each trial more patients taking these meds were hospitalized for heart failure vs those on placebo     --in the saxagliptin trial: 3.5% were hospitalized for heart failure (vs 2.8% on placebo). risk factors included prior heart failure or kidney disease     --in the alogliptin trial: 3.9% were hospitalized for heart failure (vs 3.3% on placebo) --recommendation by the FDA:     -- we should consider stopping these drugs if the patient develops heart failure ...
Read more

UPDATE: ASCVD risk factor critique

I decided to do an extensive update of my prior ASCVD (atherosclerotic cardiovascular disease) risk analysis and critique of risk calculators, with much more information about the “non-traditional” risk factors. I felt that there should be more data/clarification, since I think we are really undertreating/not preventing the most common cause of death by relying on the current ASCVD risk calculators   -- Cardiovascular risk models:      -- many of us rely on the various cardiovascular risk models to determine the appropriate approach to patients, and these are often integrated into the electronic medical records      -- these risk models have several very important limitations:          -- they are typically based on community data, eg from the Framingham study etc. But, in clinical practice, we are dealing with the individual and not the community:          ...
Read more